Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2024 Jul 5;60(7):1099.
doi: 10.3390/medicina60071099.

Quantum Medicine and Irritable Bowel Syndrome-Associated Chronic Low-Back Pain: A Pilot Observational Study on the Clinical and Bio-Psycho-Social Effects of Bioresonance Therapy

Affiliations
Observational Study

Quantum Medicine and Irritable Bowel Syndrome-Associated Chronic Low-Back Pain: A Pilot Observational Study on the Clinical and Bio-Psycho-Social Effects of Bioresonance Therapy

Giovanni Barassi et al. Medicina (Kaunas). .

Abstract

Background and Objectives: Irritable bowel syndrome (IBS) is an invasive and potentially disabling syndrome characterized by a multitude of symptoms capable of reducing the quality of life of patients. Among the most disabling symptoms of IBS is certainly physical pain, which manifests itself mainly at the abdominal level but can also appear in other areas of the body, particularly in the form of chronic low-back pain (CLBP). Among the non-invasive methods of treating organ-specific pathologies and organ-related musculoskeletal problems, the use of Bioresonance Therapy (BT)-based on the administration of self-modulating Extremely Low-Frequency Electromagnetic Fields, capable of determining a rebalance of bio-electrical and metabolic activity in the presence of various functional alterations-is currently gaining acceptance. Therefore, we decided to monitor results obtained from patients suffering from IBS and CLBP subjected to a cycle of treatments with BT. Materials and Methods: We monitored 20 patients (12 women and 8 men, average age of 51 years) suffering from CLBP and other visceral symptoms related to IBS. Patients were monitored through the use of the Bristol Stool Form Scale (BSFS), the Fecal Calprotectin test and the Short-Form Health Survey 36 (SF-36), collected before (T0) and after (T1) the execution of the cycle of treatments. They undertook a treatment protocol consisting of eight sessions of BT carried out over about a month. Results: At the end of the treatments with BT, it was possible to observe a general and significant improvement in all the parameters observed, as well as a close inversely proportional correlation between the Calprotectin values detected and the quality of life experienced by the patients in relation to their perceived IBS symptoms. Conclusions: Overall, our pilot study would seem to suggest a potential beneficial effect of BT in modulating organic and musculoskeletal symptoms derived from IBS.

Keywords: Bioresonance Therapy; Calprotectin; irritable bowel syndrome; low-back pain; quality of life.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
The Rayocomp PS 1000 Polar 4.0 Med BT device used to treat the observed patients.
Figure 2
Figure 2
GEE estimates (β ± SE) for the comparison between times of the study for the items of the SF-36.

References

    1. Saha L. Irritable bowel syndrome: Pathogenesis, diagnosis, treatment, and evidence-based medicine. World J. Gastroenterol. 2014;20:6759. doi: 10.3748/wjg.v20.i22.6759. - DOI - PMC - PubMed
    1. Barbalho S.M., Goulart R.D.A., Araújo A.C., Guiguer É.L., Bechara M.D. Irritable bowel syndrome: A review of the general aspects and the potential role of vitamin D. Expert Rev. Gastroenterol. Hepatol. 2019;13:345–359. doi: 10.1080/17474124.2019.1570137. - DOI - PubMed
    1. Priya O., Parr H., Barberio B., Black C.J., Savarino E.V., Ford A.C. Global prevalence of irritable bowel syndrome according to Rome III or IV criteria: A systematic review and meta-analysis. Lancet Gastroenterol. Hepatol. 2020;5:908–917. - PubMed
    1. Lacy B.E., Patel N.K. Rome criteria and a diagnostic approach to irritable bowel syndrome. J. Clin. Med. 2017;6:99. doi: 10.3390/jcm6110099. - DOI - PMC - PubMed
    1. Mayer E.A., Ryu H.J., Bhatt R.R. The neurobiology of irritable bowel syndrome. Mol. Psychiatry. 2023;28:1451–1465. doi: 10.1038/s41380-023-01972-w. - DOI - PMC - PubMed

Publication types

Substances

LinkOut - more resources